At a meeting of the NCI Board of Scientific Advisors March 29, NCI officials had good news to report:
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.
Two phase III trials in non-small cell lung cancer patients with cachexia found that treatment with anamorelin significantly improved lean body mass and body weight compared to placebo, in addition to improving symptom burden, including appetite. No differences in handgrip strength were observed, one of the co-primary endpoints of the study.
Tocagen Inc. expanded its phase II/III clinical trial Toca 5, and is now enrolling patients in Canada. The trial first began enrolling patients in the U.S. in December 2015.
Updated results from a phase II trial of Reolysin and paclitaxel in ovarian cancer patients showed that an intent-to-treat analysis of tumor response, as assessed by CA-125 antigen levels, demonstrated statistically significantly higher full response rates and stable disease or better rates in the test arm compared to paclitaxel alone.
Patients with advanced metastatic lung cancer treated with atezolizumab, a targeted immunotherapy drug, lived significantly longer and with fewer side effects than those who received docetaxel chemotherapy, according to a study published in The Lancet.
A phase III trial of Vyxeos Liposome for Injection demonstrated statistically significant improvements in overall survival in patients with high-risk secondary acute myeloid leukemia.
The National Comprehensive Cancer Network launched its value tool, NCCN Evidence Blocks, which will be presented at its annual conference, March 31 to April 2.
I first heard something about a red sofa that cost an impressive amount of money soon after I started to cover the controversy at the Cancer Prevention and Research Institute of Texas.
The New England Journal of Medicine said it stands by the story that has triggered investigations of a potential breach of patient confidentiality.
